Cytokine network in autoimmune haemolytic anaemia: New probable targets for therapy

Cancer Detection and Prevention

Volumn 26, Issue 4, 2002, Pages 292-298

  Toriani Terenzi, C ^a   Pozzetto, U ^a   Bianchi, M ^a,b   Fagiolo, E ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b NONE   (Italy)

Author keywords

AIHA; IFN ; IL 10; IL 12; IL 2; IL 4; Therapy

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BIOSYNTHESIS; CHILD; FEMALE; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; CHILD; CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED;

EID: 0036996438     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00086-7     Document Type: Article

References (39)

1. Mainwaring CJ, Walewska R, Snowden J, et al. Fatal cold anti-i autoimmune haemolytic anaemia complicating hairy cell leukaemia. Br J Haematol 2000;109:641-3.
2. Pavithran K, Thomas M, Vimall A, et al. Chronic lymphatic leukemia presenting as hemolytic anaemia. Indian J Med Sci 1999;53(11):490-2.
3. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95(9):2786-92.
4. Ertem M, Uysal Z, Yavuz G, et al. Immune thrombocytopenia and hemolytic anemia as a presenting manifestation of Hodgkin disease. Pediatr Hematol Oncol 2000;17(2):181-5.
5. Gloneux I, Chabbert V, Rubie H, et al. Autoimmune hemolytic anemia associated with a mature ovarian teratoma. Arch Pediatr 1998;5(1):41-4.
6. Lands R, Foust J. Renal cell carcinoma and autoimmune hemolytic anemia. South Med J 1996;89(4):444-5.
7. Zuncker S. Anemia in cancer. Cancer Invest 1985;3(3):249-60.
8. Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am 1996;10(2):365-76.
9. Calderoni A, Altermatt HJ, Pirovino M. Autoimmune processes as paraneoplastic manifestations in familiar breast carcinoma. Dtsch Med Wochenschr 1994;119(36):1194-8.
10. Sokol RJ, Booker DJ, Stamps R. Erythrocyte autoantibodies, autoimmune haemolysis, and carcinoma. J Clin Pathol 1994;47(4):340-3.
11. Hollstein M, Sidronsky D, Vogelstein B, et al. p53 mutation in human cancers. Science 1991;253:49-53.
12. Kuhn H, Kronninga A, Flannean H, et al. p53 autoantibodies in patients with autoimmune diseases: a quantitative approach. Autoimmunity 1999;31:229-35.
13. Drappa J, Vaishnaw AK, Sullivan KE, et al. Fas gene mutation in the Canale-Smith syndrome, an inherited lymphoprolipherative disorder associated with autoimmunity. N Engl J Med 1996;335:1643-9.
14. Shenoy S, Mohanakumar T, Chatila T, et al. Defective apoptosis in lymphocyte and the role of IL-12 in autoimmunne hematologic cytopenias. Clin Immunol 2001;99:266-75.
15. Theophilopulous AN. The basis of autoimmunity. Part II. Genetic predisposition. Immunol Today 1995;16:150.
16. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
17. Romagnani S. The Th1 and Th2 paradigm. Immunol Today 1997;18:263-6.
18. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227-57.
19. Viallard JF, Pellegrin JL, Ranchin V, et al. Th1 and Th2 cytokine production by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 1999;115:189-95.
20. Horwitz DA, Gray JD, Behrendsen SC, et al. Decreased production of IL-12 and other Th1-type cytokine in patients with recent onset systemic lupus erythematosus. Arthritis Rheum 1998;41:838-44.
21. Snapper CM, Mond JJ. Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1993;14:15-7.
22. Goldman M, Druet P, Gleichmann E. Th2 cells in systemic autoimmunity: insights from allogenic diseases and chemically-induced autoimmunity. Immunol Today 1991;12:223-7.
23. Fagiolo E, Toriani-Terenzi C. Enhanced IL-10 production in vitro by monocytes in autoimmune haemolytic anaemia (AIHA). Immunol Invest 1999;28:347-52.
24. Llorente L, Richaud-Patin Y, Wijdenes J, et al. Spontaneous production of IL-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993;4:421-7.
25. Howard M, O'Garra A. Biological properties of IL-10. Immunol Today 1992;13(6):198-200.
26. Ishida H, Munchamuel T, Sakaguchi S, et al. Continuous administration of anti-IL-10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10.
27. Houssiau FA, Mascart-Lemone F, Stevens M, et al. IL-12 inhibits in vitro immunoglobulin production by human lupus PBMC. Clin Exp Immunol 1997;108:375-80.
28. Trinchieri G. Biological properties and therapeutic applications of IL-12. Eur Cytokine Netw 1997;8(3):305-7.
29. Tokano Y, Morimoto S, Kaneko H, et al. Levels of IL-12 in sera of patients with SLE-relation to Th1- and Th2-derived cytokines. Clin Exp Immunol 1999;116:169-73.
30. Fagiolo E, Abenante L. Lymphocyte activation and cytokine production in autoimmune hemolytic anaemia (AIHA). Autoimmunity 1996;24:147-56.
31. Trembleau S, Germann T, Gately MK, et al. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 1995;16(8):383-6.
32. Segal BM, Dwver BK, Shevach EM. An IL-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998;187(4):537-46.
33. O'Hara RJ, Greenman J, MacDonald AW, et al. Advanced colorectal cancer is associated with impaired IL-12 and enhanced IL-10 production. Clin Cancer Res 1998;4(8):1943-8.
34. Mtzer RJ, Rakhit A, Thompson JA, et al. Randomized multicenter phase II trial of subcutaneous recombinant human IL-12 versus IFN-α2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001;21(4):257-63.
35. Tsung K, Meko JB, Peplinski GR, et al. IL-12 induces Th1-directed antitumor response. J Immunol 1997;158(7):3359-65.
36. Lebeaut A, Garaud JJ. Clinical development of IL-10. Eur Cytokine Netw 1997;8(3):303-4.
37. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998;24(3):629-39.
38. Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998;101(4):783-94.
39. Ramachandra S, Metcalf RA, Fredrickson T, et al. Requirement for increased IL-10 in the development of B-1 lymphoproliferative disease in a murine model of CLL. J Clin Invest 1996;98(8):1788-93.